A Double-blind, Multicenter, Efficacy and Safety Study of the Oral Thrombin Inhibitor, H376/95 versus Standard Therapy (Enoxaparin and Warfarin) in Subjects with Venous Thromboembolism (Thrive II)

Study identifier:SH-TPV-0005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Double-blind, Multicenter, Efficacy and Safety Study of the Oral Thrombin Inhibitor, H376/95 versus Standard Therapy (Enoxaparin and Warfarin) in Subjects with Venous Thromboembolism (Thrive II)

Medical condition

venous thromboembolism

Phase

Phase 3

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Interventional

Age

Date

Study Start Date: 01 Oct 2000

Primary Completion Date: -

Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2174&filename=CSR-SH-TPV-0005.pdf
Download
CSR-SH-TPV-0005.pdf
Download
Trial Results Summaries
Available here

A Double-blind, Multicenter, Efficacy and Safety Study of the Oral Thrombin Inhibitor, H376/95 versus Standard Therapy (Enoxaparin and Warfarin) in Subjects with Venous Thromboembolism (Thrive II)

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=2174&filename=CSR-SH-TPV-0005.pdf

CSR-SH-TPV-0005.pdf

Trial Results Summaries